Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of antiphospholipid syndrome: study protocol-Reference-Cited by-同舟云学术

Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of antiphospholipid syndrome: study protocol

Published:2022-01-10 Issue: Volume: Page:
ISSN:1593-098X
Container-title:Clinical and Experimental Rheumatology
language:en
Short-container-title:

Author:

Sciascia Savino¹,Radin Massimo²,Cecchi Irene²,Barinotti Alice²,Rubini Elena²,Rossi Daniela²,Fenoglio Roberta²,Vaccarino Antonella²,Menegatti Elisa²,Roccatello Dario²

Affiliation:

1. Center of Research of Immunopathology and Rare Diseases, Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Turin, Italy. savino.sciascia@unito.it

2. Center of Research of Immunopathology and Rare Diseases, Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Turin, Italy.

Publisher

Clinical and Experimental Rheumatology

Subject

Immunology,Immunology and Allergy,Rheumatology

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anticoagulant and non-anticoagulant therapy in thrombotic antiphospholipid syndrome: old drugs and new treatment targets;Rheumatology;2024-02-01

2. Antiphospholipid syndrome nephropathy: Current knowledge and unanswered questions;Clinical Immunology;2023-10

3. Evolution of Antiphospholipid Syndrome;Seminars in Thrombosis and Hemostasis;2023-01-16

4. B-Cells and BAFF in Primary Antiphospholipid Syndrome, Targets for Therapy?;Journal of Clinical Medicine;2022-12-20